JAK2 and breast carcinoma: It also could impact ERα+/HER2+ tumors, which account for about 10% of the ER+ breast cancers, since HER2 can be phosphorylated at tyrosine residues via JAK2 by autocrine secretion of PRL in breast tumors [23].